Center for Computational Biology, College of Biological Sciences and Technology, Beijing Forestry University, Beijing 100083, China.
Division of Endocrinology, Diabetes, and Metabolic Disease, Translational Medicine, Department of Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA; Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA 17033, USA; Molecular Biology Laboratory, Bios Biotech Multi Diagnostic Health Center, Rome 00197, Italy.
Drug Discov Today. 2018 Nov;23(11):1883-1888. doi: 10.1016/j.drudis.2018.06.011. Epub 2018 Jun 28.
Genome-wide association studies have been increasingly used to map and characterize genes that contribute to interindividual variation in drug response. Some studies have integrated the pharmacokinetic (PK) and pharmacodynamic (PD) processes of drug reactions into association mapping, gleaning new insight into how genes determine the dynamic relationship of drug effect and drug dose. Here, we present an evolutionary framework by which two distinct concepts, chronopharmacodynamics and heterochrony (describing variation in the timing and rate of developmental events), are married to comprehend the pharmacogenetic architecture of drug response. The resulting new concept, heterochronopharmacodynamics (HCPD), can better interpret how genes influence drug efficacy and drug toxicity according to the circadian rhythm of the body and changes in drug concentration.
全基因组关联研究越来越多地被用于绘制和描述导致药物反应个体间差异的基因。一些研究将药物反应的药代动力学 (PK) 和药效动力学 (PD) 过程整合到关联映射中,深入了解基因如何确定药物作用和药物剂量之间的动态关系。在这里,我们提出了一个进化框架,通过这个框架,将两个不同的概念,时间药理学和异时性(描述发育事件的时间和速度的变化),结合起来理解药物反应的遗传药理学结构。由此产生的新概念,异时药理学(HCPD),可以更好地解释基因如何根据身体的生物钟和药物浓度的变化影响药物疗效和药物毒性。